Moody Lynn & Lieberson’s Elicio Therapeutics ELTX Stock Holding History

Moody Lynn & Lieberson’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39.1K	Hold	10,000	–	–	﹤0.01%	263
2026 Q1	$107K	Hold	10,000	–	–	0.01%	246
2025 Q4	$79.6K	Hold	10,000	–	–	﹤0.01%	263
2025 Q3	$109K	Hold	10,000	–	–	0.01%	257
2025 Q2	$77.2K	Hold	10,000	–	–	﹤0.01%	257
2025 Q1	$61.6K	Buy	+10,000	New	+$77.5K	﹤0.01%	243

Other funds holding ELTX

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

MFA

Mayflower Financial Advisors Boston, Massachusetts $1.16B AUM 24.36% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Moody Lynn & Lieberson's ELTX Position: Q2 2026 in Review

Moody Lynn & Lieberson held its Elicio Therapeutics (ELTX) position steady in Q2 2026 at 10,000 shares worth $39.1K. The position accounts for ﹤0.01% of the portfolio, ranked #263.

Moody Lynn & Lieberson first reported a position in ELTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $109K in Q3 2025. 5 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

Moody Lynn & Lieberson held 10,000 shares of Elicio Therapeutics worth $39.1K as of Q2 2026.
Moody Lynn & Lieberson left its Elicio Therapeutics share count unchanged in Q2 2026.
Elicio Therapeutics made up ﹤0.01% of Moody Lynn & Lieberson's portfolio in Q2 2026, its #263 holding.
Moody Lynn & Lieberson first reported a position in Elicio Therapeutics in Q1 2025 and has held it in 6 quarters since.
Moody Lynn & Lieberson's Elicio Therapeutics position peaked at $109K in Q3 2025.
5 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Moody Lynn & Lieberson's 13F filing for Q2 2026, filed 20 Jul 2026.